Novo Nordisk A/S: PharmaVitae Profile

Table of Contents

ABOUT THIS PROFILE

• PharmaVitae Explorer database
• Chapter structure
  • Quarterly news update
  • Company introduction
  • Company sales
  • Company financials
  • Key products and competitors
• Data sourcing
  • Analyst consensus

EXECUTIVE SUMMARY

• Key findings
• Prescription pharmaceutical sales and growth rate performance, 2002 - 14
• Financial performance, 2002 - 14
• Novo Nordisk: PharmaVitae forecasts at a glance
• Strategic insight
  • (Untitled sub-section)
• SWOT analysis
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats

QUARTERLY NEWS UPDATE

• Quarterly sales update, Q2 2009
• Product developments
• Deals and alliances
  • Technology deals
• M&A activity
• Company announcements
• Future product milestones

COMPANY INTRODUCTION

• Key findings
• Background
• Key corporate developments
• M&A history
  • Divestments promote Rx pharma focus
  • Novo Nordisk and Novozymes demerger
  • Demerger of Zymogenetics
  • Acquisition of Biobras and Pharmaplan GmbH
• Current corporate structure
  • Novo Nordisk business unit structure

COMPANY SALES

• Key findings
• Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
• Product analysis
  • Product analysis, 2002 - 08
  • Product analysis, 2008 - 14
• Therapy area analysis
• Geographic analysis
• Launch/core/expiry analysis
  • Explanation of launch/core/expiry analysis
  • Launch analysis, 2008 - 14
  • Core analysis, 2008 - 14
  • Expiry analysis, 2008 - 14
  • Launch/core/expiry configuration, 2008 - 14
• Molecule type analysis
• Externalization analysis

COMPANY FINANCIALS

• Key findings
• Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002 - 08
• Operating costs and profit analysis
  • Operating costs and profit analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2002 - 08
  • Operating cost ratio and profit margin analysis, 2008 - 14
  • Operating costs and profit analysis, 2008 - 14

KEY PRODUCTS AND COMPETITORS

• Key findings
• Overview
• Diabetes market overview
  • (Untitled sub-section)
  • Key antidiabetic product classes
  • Key competitors to Novo Nordisk' s antidiabetics portfolio
• Endocrine, metabolic & genetic disorders
  • NovoRapid
  • NovoMix
  • Levemir
  • Actraphane
  • Victoza
  • Norditropin
• Hematology
  • NovoSeven

APPENDIX

• R&D pipeline
• References
• Abbreviations
• Exchange rates

TABLES

• Table: Novo Nordisk - PharmaVitae forecasts at a glance
• Table: Novo Nordisk key product developments, 2009
• Table: Novo Nordisk product deals and alliances, 2009
• Table: Novo Nordisk technology deals and alliances, 2009
• Table: Novo Nordisk M&A activity, 2009
• Table: Novo Nordisk company announcements, 2009
• Table: Novo Nordisk future product milestones, 2009 - 11
• Table: Novo Nordisk product portfolio overview ($m), 2002 - 08
• Table: Novo Nordisk product portfolio overview ($m), 2008 - 14
• Table: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2008 - 14
• Table: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2008 - 14
• Table: Novo Nordisk launch portfolio overview ($m), 2008 - 14
• Table: Novo Nordisk core portfolio overview ($m), 2008 - 14
• Table: Novo Nordisk expiry portfolio overview ($m), 2008 - 14
• Table: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2008 - 14
• Table: Novo Nordisk prescription pharmaceutical sales by source ($m), 2008 - 14
• Table: Total Novo Nordisk sales by business unit ($m), 2002 - 08
• Table: Novo Nordisk operating revenue/cost analysis ($m), 2002 - 08
• Table: Novo Nordisk operating cost ratio analysis (% of total revenues), 2002 - 08
• Table: Novo Nordisk operating cost ratio analysis (% of total revenues), 2008 - 14
• Table: Novo Nordisk operating revenue/cost analysis ($m), 2008 - 14
• Table: Key products overview
• Table: Key insulin antidiabetics in 2008
• Table: Key non-insulin antidiabetics in 2008
• Table: NovoRapid: overview
• Table: NovoRapid: sales forecast ($m), 2008 - 14
• Table: NovoMix: overview
• Table: NovoMix: sales forecast ($m), 2008 - 14
• Table: Levemir: overview
• Table: Levemir: sales forecast ($m), 2008 - 14
• Table: Actraphane: overview
• Table: Actraphane: sales forecast ($m), 2008 - 14
• Table: Victoza: overview
• Table: Victoza: sales forecast ($m), 2008 - 14
• Table: Norditropin: overview
• Table: Norditropin: sales forecast ($m), 2008 - 14
• Table: NovoSeven: overview
• Table: NovoSeven: sales forecast ($m), 2008 - 14
• Table: Key hemophilia products in 2008
• Table: Novo Nordisk' s R&D pipeline (Phase I - registration)
• Table: Exchange rates, 2009

FIGURES

• Figure: The PharmaVitae Explorer
• Figure: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Novo Nordisk' s financial performance ($m), 2002 - 14
• Figure: Novo Nordisk presence in its key target markets (% of total market revenue), 2002 - 14
• Figure: Novo Nordisk SWOT analysis
• Figure: Novo Nordisk corporate history
• Figure: Novo Nordisk corporate structure
• Figure: Pharmaceuticals business unit structure, % of total annual revenue
• Figure: Novo Nordisk prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002 - 14
• Figure: Key product sales ($m), 2002 - 14
• Figure: Novo Nordisk key sales growth drivers and resistors ($m), 2002 - 08
• Figure: Novo Nordisk key sales growth drivers and resistors ($m), 2008 - 14
• Figure: Novo Nordisk prescription pharmaceutical sales by therapy area ($m), 2002 - 14
• Figure: Novo Nordisk prescription pharmaceutical sales by geographic region ($m), 2002 - 14
• Figure: Novo Nordisk launch/core/expiry configuration ($m), 2008 - 14
• Figure: Novo Nordisk prescription pharmaceutical sales by molecule type ($m), 2002 - 14
• Figure: Novo Nordisk prescription pharmaceutical sales by source ($m), 2002 - 14
• Figure: Novo Nordisk operating revenue/cost analysis ($m), 2002 - 14
• Figure: Key competitors to Novo Nordisk in the antidiabetics market